- Cell Mol.Life Sci. 64(15):1915-1929 (2007)
- Nat.Rev.Drug Discov. 6(9):734-745 (2007)
- Eur.J.Cancer 42(18):3127-3139 (2006)
- Oncologist. 11(7):753-764 (2006)
- Trends Cell Biol. 16(6):293-300 (2006)
- Folia Histochem.Cytobiol. 47(1):81-86 (2009)
- Br.J.Cancer 101(10):1717-1723 (2009)
- The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathwayCurr.Clin.Pharmacol. 3(2):132-143 (2008)
- Biochem.Biophys.Res.Commun. 375(3):287-291 (2008)
- Nature 454(7204):656-660 (2008)
- N.Engl.J.Med. 358(19):2039-2049 (2008)
- J.Biol.Chem. 274(46):33057-33063 (1999)
- Semin.Cancer Biol. 9(3):211-220 (1999)
- Science 282(5390):946-949 (1998)
- EMBO J. 16(13):3898-3911 (1997)
- Proc.Natl.Acad.Sci.U.S.A 94(2):663-668 (1997)
- J.Leukoc.Biol. 64(2):135-146 (1998)
- Exp.Cell Res. 241(1):161-170 (1998)
- Cancer Res. 60(2):203-212 (2000)
- Nat.Genet. 25(2):153-159 (2000)


user